Onco‑Innovations Advances its Lead Candidate ONC010 Toward Clinical Development
Onco‑Innovations Limited, a Canadian biopharmaceutical enterprise listed on the NEO Exchange with a market capitalization of 51 147 164 CAD, has announced a series of pre‑clinical milestones that bring its flagship nanoparticle‑formulated PNKP inhibitor, ONC010, closer to first‑in‑human testing.
The company began comprehensive metabolic studies on June 26 2026, employing both hepatocyte and liver microsome systems across three species—human, rat, and dog—under the stewardship of Nucro‑Technics, a premier Canadian provider of IND‑enabling pre‑clinical services. These studies aim to delineate intrinsic clearance rates, identify metabolic degradation pathways, and uncover species‑specific differences that will inform subsequent toxicology, pharmacokinetics, dose‑selection, and regulatory submission strategies.
Dr. Islam Mohamed, Chief Medical Officer, emphasized that “hepatocyte and microsome studies are foundational components of modern oncology drug development. The data generated will help characterize the metabolic profile of ONC010 and potentially contribute to dose selection, safety assessment, and overall development planning.” CEO Thomas O’Shaughnessy highlighted the significance of this milestone, noting that a clear understanding of the molecule’s behavior across relevant species is essential for designing future toxicology studies and guiding clinical translation.
Simultaneously, Onco‑Innovations has positioned itself within the broader oncology landscape through media coverage. An editorial published by BioMedWire on June 25 2026 placed the company in the spotlight of the Dynamic Brand Portfolio@IBN, underscoring its commitment to pioneering cancer therapies. In early June, a NetworkNewsAudio audio press release titled “Next‑Generation DNA Repair Therapies Open New Frontiers in Oncology” featured Onco‑Innovations, discussing the broader context of PNKP inhibitor development and the company’s role in advancing DNA‑repair‑targeted treatments.
These coordinated disclosures not only signal Onco‑Innovations’ progress in the pre‑clinical realm but also reinforce its positioning as a leader in the emerging class of PNKP inhibitors. As the company moves toward initiating first‑in‑human studies, the integrated data from metabolic, pharmacokinetic, and toxicological assessments will be critical in shaping a robust clinical development plan for ONC010.
